Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518160) titled 'JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study' on April 1.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Condition: Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Intervention: Drug: JS212 for Injection+JS111 capsules (AP-L1898)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 23, 2026

Ta...